Introduction of Three Different Orientations of Nanoparticle-Conjugated Therapeutic Strategies in a Case of Triple-Negative Breast Cancer

Abstract

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with negative expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2 (HER2). Albeit chemotherapy is the main treatment for TNBC patients, the efficacy is still limited, so there is pressing to search more effective treatments. Based on the expression of specific molecules and signaling pathways in TNBC, a variety of targeted treatment strategy has emerged. In the initial targeted therapy, the administration of monoclonal antibodies has (Mabs) problems such as poor efficacy, and the combination with chemotherapy drugs has problems such as short cycle half-life, and the emergence of nanotechnology in biomedicine provides new probabilities to address these constrains. Therefore, so far, a variety of nanoparticles (NPs)-conjugated therapy strategies have emerged. In this review, it is attempted to follow the development of nanotechnology in targeted therapy by addressing some limitations accordingly, with the introduction of three NPs-conjugated therapy strategies as examples. At the same time, it also aims to provide a reference for the subsequent development of nanotechnology combined targeted therapy.